CoChat

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial

Open access
for the BIP Study Group, Arbel, Yaron, Klempfner, Robert, Erez, Aharon, Goldenberg, Ilan, Benzekry, Sagit, Shlomo, Nir, Fisman, Enrique Z., Tenenbaum, Alexander · 2016 · Cardiovascular Diabetology

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Recent data support the renewed interest in hypertriglyceridemia as a possible important therapeutic target for cardiovascular risk reduction. This study was designed to address the question of all-cause mortality during extended follow-up of the BIP trial in patients stratified by baseline triglyceride levels. METHODS: In the BIP trial 3090 patients with proven coronary artery disease were randomized to bezafibrate 400 mg/day or placebo. All-cause mortality data after 20 years of follow-up, were obtained from the National Israeli Population Registry. Patients with hypertriglyceridemia (triglycerides ≥200 mg/dL, n = 458) were equally distributed among the study groups (15 % in both placebo and bezafibrate groups). RESULTS: During follow-up 1869 patients died (952 in placebo vs. 917 in bezafibrate group). Following multivariate adjustment allocation to bezafibrate was associated with small but significant 10 % mortality risk reduction (HR 0.90; 95 % CI 0.82-0.98, p = 0.026). Variables associated with significantly increased mortality risk were history of a past MI, NYHA class, diabetes, age, higher BMI and glucose level. In patients with hypertriglyceridemia multivariate analysis demonstrated a 25 % all-cause mortality risk reduction associated with allocation to bezafibrate (HR 0.75, CI 95 % 0.60-0.94; p = 0.012). In patients without hypertriglyceridemia bezafibrate had no significant effect on long-term mortality. CONCLUSIONS: During long-term follow-up bezafibrate-allocated patients experienced a modest but significant 10 % reduction in the adjusted risk of mortality. This effect of bezafibrate was more prominent among patients with baseline hypertriglyceridemia (25 % mortality risk reduction).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-016-0332-6

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Long-term survival estimates by study drug allocation for the entire study population
Fig. 1 Long-term survival estimates by study drug allocation for the entire study populationCC BY · PubMed Central
Fig. 2 Adjusted survival probability by original study allocation of bezafibrate vs. placebo in patients with TG ≥200 mg/dL&. & Cox proportional hazard regression model adjusted for age, gender, hypertension, past MI, baseline glucose, BMI, NYHA ≥ II, HDL-C and diabetes status
Fig. 2 Adjusted survival probability by original study allocation of bezafibrate vs. placebo in patients with TG ≥200 mg/dL&. & Cox proportional hazard regression model adjusted for age, gender, hypertension, past MI, baseline glucose, BMI, NYHA ≥ II, HDL-C and diabetes statusCC BY · PubMed Central
Fig. 3 Independent effect of the adjusted risk reduction associated with bezafibrate vs. placebo treatment by pre-specified triglyceride group interaction*. P value for interaction of TG group by treatment allocation = 0.11. *Model further adjusted for age, gender, HDL-C, diabetes, past MI, BMI and glucose levels
Fig. 3 Independent effect of the adjusted risk reduction associated with bezafibrate vs. placebo treatment by pre-specified triglyceride group interaction*. P value for interaction of TG group by treatment allocation = 0.11. *Model further adjusted for age, gender, HDL-C, diabetes, past MI, BMI and glucose levelsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 41

Metadata

Authors
for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A.
Affiliations
Tel Aviv University (IL)
Corresponding author
Arbel, Yaron
Venue
Cardiovascular Diabetology
Published
2016-01-22
Volume
15
Issue
1
Pages
11-11
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2264526300
Cited by
40
References
46
Citations by year
2025: 4 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 6 · 2018: 4 · 2017: 8 · 2016: 3
FWCI
7.75
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
bezafibrate, hypertriglyceridemia, coronary artery disease, all-cause mortality, long-term follow-up, fibrates, dyslipidemia, cardiovascular risk reduction
MeSH terms
Aged, Hypolipidemic Agents, Bezafibrate, Coronary Artery Disease, Female, Follow-Up Studies, Humans, Israel, Male, Middle Aged, Registries, Risk Factors, Time Factors, Triglycerides, Hypertriglyceridemia, Biomarkers, Multivariate Analysis, Chi-Square Distribution, Proportional Hazards Models, Treatment Outcome, Risk Assessment, Kaplan-Meier Estimate, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. https://app.cochat.ai/papers/10.1186/s12933-016-0332-6
The paper
for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A. (2016). Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-016-0332-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.